Welcome to our dedicated page for ORGANON & CO SEC filings (Ticker: OGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Organon & Co. filings document the regulatory record for a NYSE-listed global healthcare company with Women's Health and General Medicines portfolios, including biosimilars. Form 8-K reports cover operating and financial results, company presentations, clinical or regulatory disclosures, material agreements, and other material events tied to the healthcare portfolio.
Proxy and governance filings describe board composition, executive compensation, shareholder voting matters, equity-award disclosures, and common stock registered under the Exchange Act. The filing record also includes disclosures on board and committee changes, audit committee review matters, capital structure, and exhibits filed in Inline XBRL.
Organon & Co. is soliciting proxies for its virtual 2026 Annual Meeting on June 9, 2026, where shareholders will vote on ten director nominees, an advisory say‑on‑pay proposal, an amended 2021 Incentive Stock Plan, and ratification of PricewaterhouseCoopers as auditor.
The company reports 2025 revenue of $6.2 billion and $1.9 billion in adjusted EBITDA, supported by strong biosimilars growth, Vtama revenue of $128 million, and disciplined cost control delivering over $200 million in savings. Organon lowered its dividend payout ratio and used about $390 million of Jada divestiture proceeds to reduce debt.
The proxy highlights a highly independent, diverse board in which 70% of directors are women and 50% are racially or ethnically diverse, extensive committee oversight of risk, cybersecurity, human capital and ESG, and an executive compensation program tied to performance, shareholder feedback and ESG-linked scorecard metrics.
Organon & Co. interim executive Juliana Papa reported a large equity compensation grant and related vesting activity. On March 31, 2026, she received 125,208 restricted stock units (RSUs), each representing a contingent right to one share of Organon common stock. These RSUs will vest in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029.
On the same date, previously granted RSUs vested and were converted into common shares through exercises of 6,378 and 10,073 RSUs. To cover tax obligations, 2,185 and 3,451 common shares were withheld at a price of $5.70 per share. After these transactions, Papa directly holds 33,235.703 shares of common stock and 20,148 RSUs.
Organon & Co. Head of R&D & CMO Juan Camilo Arjona Ferreira reported equity compensation and related share movements. On March 31, 2026, he received a grant of 200,333 Restricted Stock Units (RSUs), each representing one share of Organon common stock, vesting in three equal installments on March 31, 2027, 2028, and 2029.
On the same date, he exercised 13,431 RSUs from a prior March 31, 2025 grant, receiving an equal number of common shares. Of these, 4,820 shares of common stock were withheld at $5.70 per share to cover tax obligations. Following these transactions, he directly holds 30,047.477 shares of common stock and 200,333 RSUs.
Organon & Co. executive Daniel Karp reported several equity compensation moves involving Restricted Stock Units (RSUs) and common stock. On March 31, 2026, he received a grant of 100,166 RSUs, each representing a contingent right to one share of Organon common stock. These RSUs vest in three equal installments on March 31, 2027, 2028, and 2029.
On the same date, previously granted RSUs from March 31, 2023 and March 31, 2025 partially vested, converting 11,338 and 6,715 RSUs, respectively, into common shares. To cover tax obligations, 3,554 and 2,105 common shares were withheld at a price of $5.70 per share. After these transactions, Karp directly held 69,547.923 shares of Organon common stock, alongside the new unvested RSU grant.
Organon & Co. Chief Information Officer Rachel A. Stahler reported compensation-related stock activity. She was granted 183,639 restricted stock units (RSUs) on March 31, 2026, each representing a contingent right to one share of Organon common stock, vesting in three equal installments on March 31, 2027, 2028, and 2029.
On the same date, previously granted RSUs from March 31, 2023 and March 31, 2025 vested and were exercised into common shares. A total of 6,463 shares of common stock were withheld at a price of $5.70 per share to cover tax obligations. After these transactions, Stahler directly holds 116,105.292 shares of Organon common stock.
Organon & Co. Chief Financial Officer Matthew M. Walsh reported a series of equity compensation transactions in Organon common stock. On March 31, 2026, he was granted 321,368 restricted stock units (RSUs) and a separate grant of 83,472 RSUs, each RSU representing a contingent right to one share of common stock. These RSUs will vest in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. On the same date, portions of earlier RSU awards granted in 2023 and 2025 vested and were exercised into common stock, while 4,127 and 7,380 shares were withheld at $5.70 per share to cover tax obligations. Following these transactions, Walsh directly holds 212,746 shares of Organon common stock.
Organon & Co. Chief Human Resources Officer Aaron Falcione reported equity compensation activity involving restricted stock units (RSUs) and common stock. On March 31, 2026, he received a grant of 166,944 RSUs, each representing a contingent right to one share of Organon common stock.
The new RSUs vest in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. On the same date, previously granted RSUs vested and were converted into 6,732 and 11,193 shares of common stock. To satisfy tax obligations, 2,306 and 3,834 shares were withheld at a price of $5.70 per share.
After these transactions, Falcione directly owned 101,431.071 shares of Organon common stock and held 166,944 RSUs subject to future vesting.
Organon & Co. general counsel Kirke Weaver reported compensation-related equity activity. On March 31, 2026, Weaver received a grant of 183,639 Restricted Stock Units (RSUs), each representing a contingent right to one share of Organon common stock. These RSUs vest in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029.
On the same date, previously granted RSUs vested and were exercised into 18,513 shares of common stock. To cover tax obligations, 5,275 shares were withheld at a price based on the March 30, 2026 closing market price of $5.70 per share. After these transactions, Weaver directly owned 92,639.163 shares of Organon common stock.
Organon & Co. executive Vittorio Nisita reported routine equity compensation activity. On March 31, 2026, Nisita received a grant of 125,208 Restricted Stock Units (RSUs), each representing a contingent right to one share of Organon common stock. These RSUs will vest in three equal installments on March 31, 2027, 2028, and 2029.
On the same date, portions of earlier RSU grants from 2023 and 2025 vested, converting into a total of 13,000 shares of common stock. To satisfy tax obligations, 4,453 shares were withheld at a reference price of $5.70 per share, leaving Nisita with 70,619.158 common shares held directly after these transactions.